Verastem Inc. (VSTM)
| Bid | 7.5 |
| Market Cap | 386.95M |
| Revenue (ttm) | 10M |
| Net Income (ttm) | -130.64M |
| EPS (ttm) | -3.66 |
| PE Ratio (ttm) | -2.05 |
| Forward PE | -5.53 |
| Analyst | Buy |
| Ask | 7.6 |
| Volume | 1,278,928 |
| Avg. Volume (20D) | 825,647 |
| Open | 7.09 |
| Previous Close | 7.12 |
| Day's Range | 7.15 - 7.59 |
| 52-Week Range | 2.10 - 13.52 |
| Beta | 0.56 |
About VSTM
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel coho...
Analyst Forecast
According to 9 analyst ratings, the average rating for VSTM stock is "Buy." The 12-month stock price forecast is $14, which is an increase of 86.29% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago · seekingalpha.com
Verastem: RAMP-203 Study Could Be Next Big Win For Avutometinib CombinationVerastem, Inc.'s priority review PDUFA date of avutometinib + defactinib for treatment of patients with recurrent LGSOC is expected June 30th of 2025; At this time, no FDA advisory committee to be hel...
2 months ago · businesswire.com
Verastem Oncology to Present at the Guggenheim SMID Cap Biotech ConferenceBOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its ...